Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

BACKGROUND: T cell engagers are bispecific antibodies recognizing, with one moiety, the CD3ε chain of the T cell receptor and, with the other moiety, specific tumor surface antigens. Crosslinking of CD3 upon simultaneous binding to tumor antigens triggers T cell activation, proliferation and cytokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Leclercq, Gabrielle, Haegel, Hélène, Schneider, Anneliese, Giusti, Anna Maria, Marrer-Berger, Estelle, Boetsch, Christophe, Walz, Antje-Christine, Pulko, Vesna, Sam, Johannes, Challier, John, Ferlini, Cristiano, Odermatt, Alex, Umaña, Pablo, Bacac, Marina, Klein, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323395/
https://www.ncbi.nlm.nih.gov/pubmed/34326166
http://dx.doi.org/10.1136/jitc-2021-002582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323395/
https://www.ncbi.nlm.nih.gov/pubmed/34326166
http://dx.doi.org/10.1136/jitc-2021-002582

Ejemplares similares